ACT DMD Update with PTC (February 2014) On February 5, 2014, Dr. Robert Spiegel, Chief Medical Officer at PTC Therapeutics, presented an update about PTC’s Phase 3 study of ataluren, now known as the Ataluren Confirmatory Trial in DMD (ACT DMD). Research & Clinical Trial Webinars,Webinars 11 years ago You may also like 1:05:47 Understanding Gene Therapy, Part 3 – Galgt2 and Dup2 (December 2017) 7 years ago Research & Clinical Trial Webinars,Webinars gene therapy 50:36 Capricor Therapeutics’ HOPE-Duchenne Clinical Trial (November 2017) 7 years ago Research & Clinical Trial Webinars,Webinars 1:05:15 Wave Life Sciences (November 2017) 7 years ago Research & Clinical Trial Webinars,Webinars 59:29 FibroGen Update on Pamrevlumab & Enrolling Non-Ambulatory Study (October 2017) 7 years ago Research & Clinical Trial Webinars,Webinars 57:15 MoveDMD Trial Open-Label Extension Results (October 2017) 7 years ago Research & Clinical Trial Webinars,Webinars 1:01:20 Gene Therapy for Duchenne – PART 2: Nationwide Children’s Hospital (September 2017) 7 years ago Research & Clinical Trial Webinars,Webinars gene therapy 1:08:13 Gene Therapy for Duchenne (August 2017) 7 years ago Research & Clinical Trial Webinars,Webinars gene therapy 58:24 Nationwide Children’s Hospital Carrier Study (May 2017) 8 years ago Research & Clinical Trial Webinars,Webinars «1…1617181920…25»Page 18 of 25
by: Parent Project Muscular Dystrophy
